Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTENTION: Tivantinib + Erlotinib in Non-Squamous NSCLC
NCT01377376Phase 3Terminated
- Sponsor
- Kyowa Kirin
- Start
- Jul 2011
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tivantinib in non-small cell lung cancer (NSCLC), sponsored by Kyowa Kirin. Primary endpoint: Overall Survival. Started Jul 2011; status: terminated.
02
Drugs
tivantinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01377376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01377376.